MCID: HML002
MIFTS: 63

Hemolytic Anemia

Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hemolytic Anemia

MalaCards integrated aliases for Hemolytic Anemia:

Name: Hemolytic Anemia 38 12 29 6 15 63
Anemia, Hemolytic 44 40 73
Anemia Hemolytic 12 55

Classifications:



External Ids:

Disease Ontology 12 DOID:583
ICD10 33 D55-D59
MeSH 44 D000743
NCIt 50 C34376
SNOMED-CT 68 61261009
UMLS 73 C0002878

Summaries for Hemolytic Anemia

PubMed Health : 63 About hemolytic anemia: Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is over.Red blood cells are disc-shaped and look like doughnuts without holes in the center. These cells carry oxygen to your body. They also remove carbon dioxide (a waste product) from your body.Red blood cells are made in the bone marrow—a sponge-like tissue inside the bones. They live for about 120 days in the bloodstream and then die.White blood cells and platelets (PLATE-lets) also are made in the bone marrow. White blood cells help fight infections. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding.When blood cells die, the body's bone marrow makes more blood cells to replace them. However, in hemolytic anemia, the bone marrow can't make red blood cells fast enough to meet the body's needs.Hemolytic anemia can lead to many health problems, such as fatigue (tiredness), pain, irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, and heart failure.

MalaCards based summary : Hemolytic Anemia, also known as anemia, hemolytic, is related to congenital nonspherocytic hemolytic anemia and congenital hemolytic anemia, and has symptoms including icterus An important gene associated with Hemolytic Anemia is SPTB (Spectrin Beta, Erythrocytic), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Nitric Oxide and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include bone, heart and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 Hemolytic anemia is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs),... more...

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 533)
# Related Disease Score Top Affiliating Genes
1 congenital nonspherocytic hemolytic anemia 33.9 G6PD GPI NT5C3A PKLR
2 congenital hemolytic anemia 33.8 ANK1 G6PD GPI HBB PIEZO1 PKLR
3 pyruvate kinase deficiency of red cells 33.8 G6PD PKLR
4 hereditary spherocytosis 33.1 ANK1 EPB42 G6PD HBB PKLR SLC4A1
5 glucosephosphate dehydrogenase deficiency 33.0 G6PD HBB
6 pyropoikilocytosis, hereditary 32.7 SPTA1 SPTB
7 glucosephosphate isomerase deficiency 32.5 G6PD GPI
8 glutathione synthetase deficiency 32.4 G6PD GSS
9 spherocytosis, type 3 32.0 HBB SPTA1
10 malaria 30.5 ADAMTS13 G6PD HBB PKLR SLC4A1
11 hereditary elliptocytosis 30.4 ANK1 SLC4A1 SPTA1 SPTB
12 splenic infarction 30.3 HBB PIEZO1
13 beta-thalassemia 30.3 G6PD HBB SPTB
14 kernicterus 29.9 G6PD SLC4A1
15 hemolytic anemia, nonspherocytic, due to hexokinase deficiency 12.6
16 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 12.6
17 warm antibody hemolytic anemia 12.6
18 uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to 12.5
19 renal tubular acidosis, distal, with hemolytic anemia 12.5
20 adenylate kinase deficiency, hemolytic anemia due to 12.5
21 drug-induced autoimmune hemolytic anemia 12.5
22 glutathione synthetase deficiency of erythrocytes, hemolytic anemia due to 12.5
23 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.5
24 hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency 12.5
25 anemia, autoimmune hemolytic 12.4
26 mixed-type autoimmune hemolytic anemia 12.2
27 systemic lupus erythematosus with hemolytic anemia 1 12.2
28 autoimmune hemolytic anemia, warm type 12.2
29 hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities 12.2
30 adenosine deaminase, elevated, hemolytic anemia due to 12.2
31 hemolytic anemia with thermal sensitivity of red cells 12.2
32 hemolytic anemia, congenital, x-linked 12.2
33 hemolytic anemia due to glutathione reductase deficiency 12.2
34 lymphopenic hypergammaglobulinemia, antibody deficiency, autoimmune hemolytic anemia, and glomerulonephritis 12.1
35 neonatal autoimmune hemolytic anemia 12.1
36 autoimmune hemolytic anemia-autoimmune thrombocytopenia-primary immunodeficiency syndrome 12.1
37 hemolytic anemia due to erythrocyte adenosine deaminase overproduction 12.1
38 triosephosphate isomerase deficiency 12.1
39 thrombotic thrombocytopenic purpura, congenital 12.0
40 paroxysmal cold hemoglobinuria 12.0
41 glut1 deficiency syndrome 2 12.0
42 evans' syndrome 12.0
43 glucose phosphate isomerase deficiency 12.0
44 glutathione peroxidase deficiency 11.9
45 cold agglutinin disease 11.9
46 hemolytic-uremic syndrome 11.9
47 anemia, nonspherocytic hemolytic, due to g6pd deficiency 11.9
48 rh-null, regulator type 11.8
49 immunodysregulation, polyendocrinopathy, and enteropathy, x-linked 11.8
50 phosphoglycerate kinase deficiency 11.7

Graphical network of the top 20 diseases related to Hemolytic Anemia:



Diseases related to Hemolytic Anemia

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:


icterus

GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 10.33 AK1
2 Decreased viability GR00221-A-1 10.33 PKLR
3 Decreased viability GR00221-A-2 10.33 PKLR
4 Decreased viability GR00221-A-4 10.33 PKLR
5 Decreased viability GR00240-S-1 10.33 ALDOA CD59
6 Decreased viability GR00301-A 10.33 PKLR
7 Decreased viability GR00342-S-1 10.33 PGK1
8 Decreased viability GR00342-S-3 10.33 PGK1 PKLR
9 Decreased viability GR00402-S-2 10.33 ADAMTS13 AK1 ALDOA ANK1 CD59 EPB42
10 no effect GR00402-S-1 9.62 ADAMTS13 AK1 ALDOA ANK1 CD59 EPB42
11 Increased simian virus 40 (SV40) infection GR00356-A-2 9.13 HK1 PGK1 PKLR

MGI Mouse Phenotypes related to Hemolytic Anemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.07 ADAMTS13 ANK1 CD59 EPB42 G6PD GPI
2 homeostasis/metabolism MP:0005376 10.03 ADAMTS13 AK1 ANK1 CD59 EPB42 G6PD
3 immune system MP:0005387 9.65 ADAMTS13 ANK1 EPB42 GPI HK1 PIEZO1
4 mortality/aging MP:0010768 9.4 ADAMTS13 ANK1 CD59 G6PD GCLC GPI

Drugs & Therapeutics for Hemolytic Anemia

PubMedHealth treatment related to Hemolytic Anemia: 63

Treatments for hemolytic anemia include blood transfusions, medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery, blood and marrow stem cell transplants, and lifestyle changes.People who have mild hemolytic anemia may not need treatment, as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nitric Oxide Approved Phase 4 10102-43-9 145068
2
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 2 198153-51-4 5360545
3
Ribavirin Approved Phase 4,Phase 3,Phase 2,Not Applicable 36791-04-5 37542
4
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
5
Mannitol Approved, Investigational Phase 4 69-65-8 453 6251
6
Racepinephrine Approved Phase 4 329-65-7 838
7
Prilocaine Approved Phase 4 721-50-6 4906
8
Iron Approved Phase 4,Phase 2 7439-89-6 23925
9
Metformin Approved Phase 4 657-24-9 14219 4091
10
Etonogestrel Approved, Investigational Phase 4 54048-10-1 6917715 40976
11
Desogestrel Approved Phase 4 54024-22-5 40973
12 Antioxidants Phase 4,Phase 3,Phase 2
13
Bilirubin Phase 4 635-65-4 5280352
14 Pharmaceutical Solutions Phase 4,Phase 3,Phase 1
15 Protective Agents Phase 4,Phase 3,Phase 2,Not Applicable
16 Immunologic Factors Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
17 Antimetabolites Phase 4,Phase 3,Phase 2,Not Applicable
18 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
19 Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
20 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Not Applicable
21 Hormones Phase 4,Phase 3,Phase 2,Not Applicable
22 interferons Phase 4,Phase 3,Phase 2,Not Applicable
23 Antiviral Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
24 Interferon-alpha Phase 4,Phase 3,Phase 2
25 Natriuretic Agents Phase 4
26 Epinephryl borate Phase 4
27 diuretics Phase 4
28 Liver Extracts Phase 4,Phase 3,Phase 2
29 Iron Chelating Agents Phase 4,Phase 2
30 Hypoglycemic Agents Phase 4
31 Progestins Phase 4
32
Ethylene Phase 4 74-85-1 6325
33 Contraceptives, Oral Phase 4
34 Contraceptive Agents Phase 4
35
Methylprednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 83-43-2 6741
36
Methylprednisolone hemisuccinate Approved Phase 3,Phase 2,Not Applicable 2921-57-5
37
Prednisolone phosphate Approved, Vet_approved Phase 3,Phase 2,Not Applicable 302-25-0
38
Prednisolone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 50-24-8 5755
39
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 6055-19-2, 50-18-0 2907
40
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
41
Prednisone Approved, Vet_approved Phase 3,Phase 2,Not Applicable 53-03-2 5865
42
rituximab Approved Phase 3,Phase 2 174722-31-7 10201696
43
Primaquine Approved Phase 3,Phase 2 90-34-6 4908
44
Mineral oil Approved, Vet_approved Phase 3 8042-47-5
45
Tocopherol Approved, Investigational Phase 3,Phase 2 1406-66-2 14986
46
Vidarabine Approved, Investigational Phase 3,Phase 2 24356-66-9 32326 21704
47
Ofatumumab Approved Phase 3,Phase 2 679818-59-8 6918251
48
Fludarabine Approved Phase 3,Phase 2 75607-67-9, 21679-14-1 30751
49
Chlorambucil Approved Phase 3,Phase 2 305-03-3 2708
50
Dapsone Approved, Investigational Phase 3 80-08-0 2955

Interventional clinical trials:

(show top 50) (show all 111)
# Name Status NCT ID Phase Drugs
1 Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
2 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Completed NCT00491179 Phase 4 Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
3 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin for Treatment-Naïve Hemodialysis Patients With Chronic Hepatitis C Completed NCT00491244 Phase 4 Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a
4 A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) in Patients With Chronic Hepatitis C (CHC) Genotype 1 and Human Immunodeficiency Virus-1 (HIV-1) Co-infection Completed NCT00353418 Phase 4 Peginterferon alfa-2a;Ribavirin;Ribavirin
5 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
6 Low-Dose Peginterferon and Ribavirin to Treat Chronic Hepatitis C in Patients Infected With HCV Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
7 Pegylated Interferon and Ribavirin to Treat Chronic Hepatitis C With and Without Kidney Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
8 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
9 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalassemia Major Recruiting NCT02984475 Phase 4 Metformin
10 Contraception in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
11 Rituximab in Auto-Immune Hemolytic Anemia Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
12 Prednisolone +/- Addition of Anti-CD20 Antibody, Rituximab, in Patients With Immune Hemolytic Anemia Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
13 Combination Drug Therapy for Patients With Hepatitis C Completed NCT00001729 Phase 3 Ribavirin
14 Eight Week Primaquine Regimen for the Treatment of Vivax Malaria Completed NCT00158587 Phase 3 primaquine
15 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) Completed NCT00135707 Phase 3 Dietary Supplement/Vitamins;Placebo for Vitamin C and Vitamin E
16 Doppler or Amniocentesis to Predict Fetal Anemia Completed NCT00295516 Phase 3
17 Ofatumumab Added to Fludarabine-Cyclophosphamide vs Fludarabine-Cyclophosphamide Combination in Relapsed Subjects With Chronic Lymphocytic Leukemia Completed NCT00824265 Phase 3 OFC Infusion;FC infusion
18 Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy Completed NCT01039376 Phase 3
19 Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia Completed NCT00748189 Phase 3 chlorambucil, tablets;ofatumumab (GSK1841157) infusion
20 Lapdap and Coartemether for Uncomplicated Malaria Completed NCT00118794 Phase 3 Chlorproguanil-dapsone (Lapdap);Lumefantrine-artemether (Coartemether )
21 Eculizumab in Shiga-toxin Related Hemolytic and Uremic Syndrome Pediatric Patients - ECULISHU Completed NCT02205541 Phase 3 Eculizumab;Placebo
22 Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia Completed NCT01313689 Phase 3 Ofatumumab;Physicians' Choice
23 A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVE Recruiting NCT03312907 Phase 3 Belimumab;Rituximab;Rituximab-placebo;Standard therapy (Including Immunosuppressants);Standard therapy (Excluding Immunosuppressants);Steriod Taper
24 A Study to Evaluate the Safety and Tolerability of Prophylactic Emicizumab in Hemophilia A Patients With Inhibitors Active, not recruiting NCT03191799 Phase 3 Emicizumab
25 A Phase 3, Randomized, Controlled Study of Prophylactic and On-demand Treatment of cTTP With BAX 930 (rADAMTS13) Active, not recruiting NCT03393975 Phase 3
26 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA Not yet recruiting NCT03764618 Phase 3 Fostamatinib disodium;Placebo
27 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
28 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
29 Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
30 Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
31 A Randomized Trial of LOVAZA in Pediatric Sickle Cell Disease (SCD) Unknown status NCT01202812 Phase 2
32 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab
33 Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia (CLL) That Did Not Respond to Fludarabine, CLL With Autoimmune Haemolytic Anemia (AIHA) or Richter's Transformation (RT) Completed NCT00309881 Phase 2 cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
34 High Dose Ribavirin in the Treatment of Chronic Hepatitis C Completed NCT00944684 Phase 2 High ribavirin dose;Standard ribavirin dose
35 Bendamustine and Rituximab Combination Therapy for Cold Agglutinin Disease Completed NCT02689986 Phase 2 Bendamustine, Rituximab
36 Study of Deferasirox Relative to Subcutaneous Deferoxamine in Sickle Cell Disease Patients Completed NCT00110617 Phase 2 Deferasirox (ICL670);Deferoxamine (DFO)
37 Clinical Trial to Study the Safety and Tolerability of Memantin Mepha® in Sickle Cell Disease Patients Completed NCT02615847 Phase 2 Memantinhydrochlorid
38 Therapy for Chronic Cold Agglutinin Disease Completed NCT00373594 Phase 2 Rituximab;Fludarabine
39 Vitamin E Supplement in Patients With Cirrhosis and Acanthocytosis Completed NCT01463735 Phase 2
40 Unrelated Hematopoietic Stem Cell Transplantation(HSCT) for Genetic Diseases of Blood Cells Completed NCT00730314 Phase 1, Phase 2
41 Glutamine Therapy for Hemolysis-Associated Pulmonary Hypertension Completed NCT01048905 Phase 2 L-Glutamine;L-Glutamine
42 Rituximab in Adult Acquired Idiopathic Thrombotic Thrombocytopenic Purpura Completed NCT00907751 Phase 2 rituximab
43 Bortezomib to Treat Significant Complication of HSCT Completed NCT01929980 Phase 2 Bortezomib
44 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
45 Efficacy of PegInterferon-Ribavirin-Boceprevir Therapy in Patients Infected With G1 HCV With Cirrhosis, Awaiting Liver Transplantation Completed NCT01463956 Phase 2 Boceprevir;Ribavirin
46 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) Completed NCT01520922 Phase 2 Bendamustine
47 Efficacy and Safety of HyQvia (Immunoglobulin 10% With Recombinant Hyaluronidase) in Multifocal Motor Neuropathy (MMN) Completed NCT02556437 Phase 2 HyQvia;Subcuvia
48 Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial Completed NCT02111161 Phase 2 IVIG (Privigen);Saline 0.9%
49 Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children Completed NCT00502593 Phase 2
50 A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia Completed NCT01563055 Phase 2 chlorambucil, tablets;ofatumumab (GSK1841157) infusion

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemolytic Anemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: anemia, hemolytic

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

# Genetic test Affiliating Genes
1 Hemolytic Anemia 29

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

41
Bone, Heart, Bone Marrow, Testes, Liver, Spleen, B Cells

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

(show top 50) (show all 2138)
# Title Authors Year
1
Hepatosplenic T cell lymphoma: a unifying entity in a patient with hemolytic anemia, massive splenomegaly, and liver dysfunction. ( 29766398 )
2018
2
Increased number of tissue factor protein expressing thrombocytes in canine idiopathic immune mediated hemolytic anemia. ( 29695321 )
2018
3
Importance of the Average Glucose Level and Estimated Glycated Hemoglobin in a Diabetic Patient with Hereditary Hemolytic Anemia and Liver Cirrhosis. ( 29225250 )
2018
4
Cytomegalovirus reactivation can be a cause of DAT-negative hemolytic anemia in patients with chronic lymphocytic leukemia. ( 29911929 )
2018
5
Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. ( 29340837 )
2018
6
Paraneoplastic Auto-immune Hemolytic Anemia: An Unusual Sequela of Enteric Duplication Cyst. ( 29277816 )
2018
7
Methylene blue-induced Heinz body hemolytic anemia in a premature neonate. ( 29314195 )
2018
8
Successful treatment of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation with bortezomib. ( 29345206 )
2018
9
Microangiopathic Hemolytic Anemia Following Three Different Species of Hump-Nosed Pit Viper (Genus: Hypnale) Envenoming in Sri Lanka. ( 29361387 )
2018
10
Hemolytic anemia due to native valve subacute endocarditis with<i>Actinomyces israelii</i>infection. ( 29445480 )
2018
11
A Case Report of Congenital Non-spherocytic Hemolytic Anemia in a Patient from India. ( 29904619 )
2018
12
Effects of therapeutic plasma exchange on serum immunoglobulin concentrations in a dog with refractory immune-mediated hemolytic anemia. ( 29641335 )
2018
13
Identification of a Novel Mutation in the SEC23B Gene Associated With Congenital Dyserythropoietic Anemia Type II Through the Use of Next-generation Sequencing Panel in an Undiagnosed Case of Nonimmune Hereditary Hemolytic Anemia. ( 29846281 )
2018
14
Mixed IgM cold and IgG warm autoimmune hemolytic anemia complicated by acral gangrene. ( 29683507 )
2018
15
Ominous comorbidities: Small ventricular septal defect and warm autoimmune hemolytic anemia. ( 29440848 )
2018
16
Life-threatening autoimmune warm hemolytic anemia following treatment for multiple sclerosis with alemtuzumab. ( 29359614 )
2018
17
Factors associated with immune hemolytic anemia after pediatric liver transplantation. ( 29885007 )
2018
18
Splenic myeloid metaplasia in warm autoimmune hemolytic anemia (wAIHA): a retrospective study. ( 29662860 )
2018
19
Molecular detection of Mycoplasma ovis in an outbreak of hemolytic anemia in sheep from Veracruz, Mexico. ( 29934796 )
2018
20
R Inguinal/R Scrotum Extramammary Paget's Disease with Diffuse Spine Metastasis Complicated by Microangiopathic Hemolytic Anemia. ( 29805822 )
2018
21
Spurious thrombocytosis in the setting of hemolytic anemia and microcytosis secondary to extensive burn injury. ( 29391327 )
2018
22
Simultaneous early-onset severe autoimmune hemolytic anemia and albuminuria during alemtuzumab treatment for multiple sclerosis. ( 29359617 )
2018
23
Eluate testing with monospecific antisera unmasks multiple immunoglobulin classes and identifies frequent IgA involvement in severe autoimmune hemolytic anemia. ( 29716828 )
2018
24
Whole-exome analysis to detect congenital hemolytic anemia mimicking congenital dyserythropoietic anemia. ( 29936674 )
2018
25
Features of peripheral CD8<sup>+</sup>CD57<sup>+</sup> lymphocytes in patients with autoimmune hemolytic anemia. ( 29845877 )
2018
26
Efficacy of D- red blood cell transfusion and rituximab therapy in autoimmune hemolytic anemia with anti-D and panreactive autoantibodies arising after hematopoietic stem cell transplant. ( 29664112 )
2018
27
Microangiopathic hemolytic anemia as initial presentation of recurrent colon cancer. ( 29963526 )
2018
28
Influence of immune-mediated hemolytic anemia on flow velocities in the portal vein and caudal vena cava measured by use of pulsed-wave Doppler ultrasonography in dogs. ( 29688778 )
2018
29
Durable responses in refractory autoimmune hemolytic anemia with alemtuzumab. ( 29334337 )
2018
30
Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from 8 Italian Reference Centers. ( 29981267 )
2018
31
Should Giant Cell Hepatitis With Autoimmune Hemolytic Anemia Be Considered a Pediatric Autoimmune Liver Disease? ( 29394216 )
2018
32
Case-control study of plasma mean platelet component concentration and survival analysis for dogs with immune-mediated hemolytic anemia. ( 29772969 )
2018
33
Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly. ( 30527923 )
2018
34
Acute Brucellosis Presenting as an Autoimmune Hemolytic Anemia. ( 30498608 )
2018
35
Severe warm-antibody autoimmune hemolytic anemia due to multicentric Castleman disease: Responding to rituximab. ( 30486744 )
2018
36
A Unique Triad: Ulcerative Colitis, Primary Sclerosing Cholangitis, and Autoimmune Hemolytic Anemia. ( 29552430 )
2018
37
Complications of a severe autoimmune hemolytic anemia crisis: transfusional iron overload and gangrenous cholecystitis. ( 30291762 )
2018
38
Complement Activation and Inhibition in Autoimmune Hemolytic Anemia: Focus on Cold Agglutinin Disease. ( 30032751 )
2018
39
High efficacy of eculizumab treatment for fulminant hemolytic anemia in primary cold agglutinin disease. ( 30324459 )
2018
40
Safety and Efficacy of Laparoscopic Oophorocystectomy for Ovarian Dermoid Cyst Associated With Autoimmune Hemolytic Anemia. ( 30254931 )
2018
41
Bartonella endocarditis in a child with tetralogy of Fallot complicated by PR3-ANCA positive serology, autoimmune hemolytic anemia, and acute kidney injury. ( 29988634 )
2018
42
Essential thrombocythemia, hemolytic anemia and hepatic cirrhosis: Could there be an association? ( 30344986 )
2018
43
Anticardiolipin antibodies in concurrent poststreptococcal glomerulonephritis and autoimmune hemolytic anemia: A case report. ( 29557617 )
2018
44
Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. ( 30291113 )
2018
45
Autoimmune hemolytic anemia (AIHA) following allogeneic hematopoietic stem cell transplantation (HSCT): A retrospective analysis and a proposal of treatment on behalf of the Grupo Español De Trasplante de Medula Osea en Niños (GETMON) and the Grupo Español de Trasplante Hematopoyetico (GETH). ( 29573905 )
2018
46
Acute Hepatitis Caused by Genotype 4 HCV Presenting with Microangiopathic Hemolytic Anemia. ( 30370312 )
2018
47
Artesunate-Induced Severe Autoimmune Hemolytic Anemia in Complicated Malaria. ( 30405291 )
2018
48
Venous thromboembolic events during warm autoimmune hemolytic anemia. ( 30408135 )
2018
49
Delayed Hemolytic Anemia after Treatment with Artesunate: Case Report and Literature Review. ( 30411691 )
2018
50
Flurbiprofen-Associated Hemolytic Anemia. ( 30418224 )
2018

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

6 (show top 50) (show all 140)
# Gene Variation Type Significance SNP ID Assembly Location
1 HBB NM_000518.4(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
2 HBB NM_000518.4(HBB): c.127T> C (p.Phe43Leu) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995
3 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh37 Chromosome 11, 5247995: 5247995
4 HBB NM_000518.4(HBB): c.127T> G (p.Phe43Val) single nucleotide variant Pathogenic rs33924146 GRCh38 Chromosome 11, 5226765: 5226765
5 SLC4A1 NM_000342.3(SLC4A1): c.166A> G (p.Lys56Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs5036 GRCh37 Chromosome 17, 42338945: 42338945
6 SLC4A1 NM_000342.3(SLC4A1): c.166A> G (p.Lys56Glu) single nucleotide variant Conflicting interpretations of pathogenicity rs5036 GRCh38 Chromosome 17, 44261577: 44261577
7 SLC4A1 NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45562031 GRCh37 Chromosome 17, 42338993: 42338993
8 SLC4A1 NM_000342.3(SLC4A1): c.118G> A (p.Glu40Lys) single nucleotide variant Conflicting interpretations of pathogenicity rs45562031 GRCh38 Chromosome 17, 44261625: 44261625
9 SLC4A1 NM_000342.3(SLC4A1): c.2561C> T (p.Pro854Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs2285644 GRCh37 Chromosome 17, 42328621: 42328621
10 SLC4A1 NM_000342.3(SLC4A1): c.2561C> T (p.Pro854Leu) single nucleotide variant Conflicting interpretations of pathogenicity rs2285644 GRCh38 Chromosome 17, 44251253: 44251253
11 SLC4A1 NM_000342.3(SLC4A1): c.2701C> T (p.Arg901Trp) single nucleotide variant Uncertain significance rs201265160 GRCh37 Chromosome 17, 42327861: 42327861
12 SLC4A1 NM_000342.3(SLC4A1): c.2701C> T (p.Arg901Trp) single nucleotide variant Uncertain significance rs201265160 GRCh38 Chromosome 17, 44250493: 44250493
13 SLC4A1 NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=) single nucleotide variant Benign/Likely benign rs45519733 GRCh37 Chromosome 17, 42327850: 42327850
14 SLC4A1 NM_000342.3(SLC4A1): c.2712C> T (p.Tyr904=) single nucleotide variant Benign/Likely benign rs45519733 GRCh38 Chromosome 17, 44250482: 44250482
15 SLC4A1 NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=) single nucleotide variant Benign/Likely benign rs45497993 GRCh37 Chromosome 17, 42327874: 42327874
16 SLC4A1 NM_000342.3(SLC4A1): c.2688T> C (p.Asp896=) single nucleotide variant Benign/Likely benign rs45497993 GRCh38 Chromosome 17, 44250506: 44250506
17 SLC4A1 NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile) single nucleotide variant Benign/Likely benign rs5026 GRCh37 Chromosome 17, 42328598: 42328598
18 SLC4A1 NM_000342.3(SLC4A1): c.2584G> A (p.Val862Ile) single nucleotide variant Benign/Likely benign rs5026 GRCh38 Chromosome 17, 44251230: 44251230
19 SLC4A1 NM_000342.3(SLC4A1): c.1953C> T (p.His651=) single nucleotide variant Benign/Likely benign rs5021 GRCh37 Chromosome 17, 42331968: 42331968
20 SLC4A1 NM_000342.3(SLC4A1): c.1953C> T (p.His651=) single nucleotide variant Benign/Likely benign rs5021 GRCh38 Chromosome 17, 44254600: 44254600
21 SLC4A1 NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=) single nucleotide variant Benign/Likely benign rs35807245 GRCh38 Chromosome 17, 44255703: 44255703
22 SLC4A1 NM_000342.3(SLC4A1): c.1770G> A (p.Lys590=) single nucleotide variant Benign/Likely benign rs35807245 GRCh37 Chromosome 17, 42333071: 42333071
23 SLC4A1 NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=) single nucleotide variant Benign/Likely benign rs5017 GRCh37 Chromosome 17, 42335135: 42335135
24 SLC4A1 NM_000342.3(SLC4A1): c.1323G> A (p.Leu441=) single nucleotide variant Benign/Likely benign rs5017 GRCh38 Chromosome 17, 44257767: 44257767
25 SLC4A1 NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=) single nucleotide variant Benign/Likely benign rs5015 GRCh37 Chromosome 17, 42335387: 42335387
26 SLC4A1 NM_000342.3(SLC4A1): c.1249C> T (p.Leu417=) single nucleotide variant Benign/Likely benign rs5015 GRCh38 Chromosome 17, 44258019: 44258019
27 SLC4A1 NM_000342.3(SLC4A1): c.924G> A (p.Leu308=) single nucleotide variant Benign/Likely benign rs5013 GRCh37 Chromosome 17, 42335944: 42335944
28 SLC4A1 NM_000342.3(SLC4A1): c.924G> A (p.Leu308=) single nucleotide variant Benign/Likely benign rs5013 GRCh38 Chromosome 17, 44258576: 44258576
29 SLC4A1 NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala) single nucleotide variant Benign/Likely benign rs5035 GRCh37 Chromosome 17, 42338998: 42338998
30 SLC4A1 NM_000342.3(SLC4A1): c.113A> C (p.Asp38Ala) single nucleotide variant Benign/Likely benign rs5035 GRCh38 Chromosome 17, 44261630: 44261630
31 SLC4A1 NM_000342.3(SLC4A1): c.16-14G> A single nucleotide variant Benign/Likely benign rs145502796 GRCh38 Chromosome 17, 44262740: 44262740
32 SLC4A1 NM_000342.3(SLC4A1): c.16-14G> A single nucleotide variant Benign/Likely benign rs145502796 GRCh37 Chromosome 17, 42340108: 42340108
33 SLC4A1 NM_000342.3(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 GRCh37 Chromosome 17, 42325994: 42325994
34 SLC4A1 NM_000342.3(SLC4A1): c.*1832G> A single nucleotide variant Uncertain significance rs886052988 GRCh38 Chromosome 17, 44248626: 44248626
35 SLC4A1 NM_000342.3(SLC4A1): c.*1721G> A single nucleotide variant Likely benign rs62078947 GRCh37 Chromosome 17, 42326105: 42326105
36 SLC4A1 NM_000342.3(SLC4A1): c.*1721G> A single nucleotide variant Likely benign rs62078947 GRCh38 Chromosome 17, 44248737: 44248737
37 SLC4A1 NM_000342.3(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 GRCh37 Chromosome 17, 42326150: 42326150
38 SLC4A1 NM_000342.3(SLC4A1): c.*1676A> G single nucleotide variant Uncertain significance rs745898810 GRCh38 Chromosome 17, 44248782: 44248782
39 SLC4A1 NM_000342.3(SLC4A1): c.*1606_*1608dupAAA duplication Uncertain significance rs57466226 GRCh37 Chromosome 17, 42326218: 42326220
40 SLC4A1 NM_000342.3(SLC4A1): c.*1606_*1608dupAAA duplication Uncertain significance rs57466226 GRCh38 Chromosome 17, 44248850: 44248852
41 SLC4A1 NM_000342.3(SLC4A1): c.*1608delA deletion Uncertain significance rs886052989 GRCh37 Chromosome 17, 42326218: 42326218
42 SLC4A1 NM_000342.3(SLC4A1): c.*1608delA deletion Uncertain significance rs886052989 GRCh38 Chromosome 17, 44248850: 44248850
43 SLC4A1 NM_000342.3(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 GRCh38 Chromosome 17, 44249260: 44249260
44 SLC4A1 NM_000342.3(SLC4A1): c.*1198A> T single nucleotide variant Uncertain significance rs886052992 GRCh37 Chromosome 17, 42326628: 42326628
45 SLC4A1 NM_000342.3(SLC4A1): c.*897G> A single nucleotide variant Likely benign rs5030 GRCh38 Chromosome 17, 44249561: 44249561
46 SLC4A1 NM_000342.3(SLC4A1): c.*897G> A single nucleotide variant Likely benign rs5030 GRCh37 Chromosome 17, 42326929: 42326929
47 SLC4A1 NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 GRCh38 Chromosome 17, 44253219: 44253219
48 SLC4A1 NM_000342.3(SLC4A1): c.2210C> T (p.Ala737Val) single nucleotide variant Uncertain significance rs886052997 GRCh37 Chromosome 17, 42330587: 42330587
49 SLC4A1 NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 GRCh38 Chromosome 17, 44255836: 44255836
50 SLC4A1 NM_000342.3(SLC4A1): c.1637A> G (p.Asp546Gly) single nucleotide variant Uncertain significance rs886052998 GRCh37 Chromosome 17, 42333204: 42333204

Expression for Hemolytic Anemia

Search GEO for disease gene expression data for Hemolytic Anemia.

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 15)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.81 AK1 ALDOA G6PD GCLC GPI GSS
2
Show member pathways
12.66 ALDOA G6PD GPI HK1 PGK1 PKLR
3
Show member pathways
12.44 ALDOA GPI HK1 PGK1 PKLR
4 12.33 ALDOA G6PD HBB HK1
5
Show member pathways
11.82 ANK1 SPTA1 SPTB
6
Show member pathways
11.76 ALDOA G6PD GPI HK1 PGK1 PKLR
7 11.7 ALDOA HK1 PGK1
8
Show member pathways
11.57 ALDOA HK1 PGK1 PKLR
9 11.48 ALDOA HK1 PGK1
10
Show member pathways
11.47 ALDOA G6PD GPI
11
Show member pathways
11.12 HBB RHAG SLC4A1
12 10.97 ANK1 SPTA1 SPTB
13
Show member pathways
10.66 PGK1 PKLR
14 10.13 G6PD GPI HK1 PGK1
15 10.11 G6PD GPI HK1

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.96 AK1 ALDOA CD59 G6PD GPI GSS
2 ficolin-1-rich granule lumen GO:1904813 9.61 ALDOA GPI HBB
3 cytoplasmic side of plasma membrane GO:0009898 9.5 ANK1 G6PD SPTA1
4 spectrin GO:0008091 9.4 SPTA1 SPTB
5 intrinsic component of the cytoplasmic side of the plasma membrane GO:0031235 9.37 SPTA1 SPTB
6 cortical cytoskeleton GO:0030863 9.13 EPB42 SLC4A1 SPTA1
7 spectrin-associated cytoskeleton GO:0014731 8.8 ANK1 SPTA1 SPTB
8 cytosol GO:0005829 10 AK1 ALDOA ANK1 G6PD GCLC GPI

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.76 G6PD GPI HK1 PKLR
2 regulation of cell shape GO:0008360 9.73 ALDOA EPB42 SPTA1
3 ER to Golgi vesicle-mediated transport GO:0006888 9.73 ANK1 CD59 SPTA1 SPTB
4 muscle cell cellular homeostasis GO:0046716 9.55 ALDOA PGK1
5 actin filament capping GO:0051693 9.54 SPTA1 SPTB
6 gluconeogenesis GO:0006094 9.54 ALDOA GPI PGK1
7 regulation of blood vessel size GO:0050880 9.52 GCLC HBB
8 glutathione biosynthetic process GO:0006750 9.51 GCLC GSS
9 bicarbonate transport GO:0015701 9.5 HBB RHAG SLC4A1
10 erythrocyte maturation GO:0043249 9.49 EPB42 G6PD
11 response to xenobiotic stimulus GO:0009410 9.48 GCLC GSS
12 response to cadmium ion GO:0046686 9.43 GCLC GPI GSS
13 cellular ion homeostasis GO:0006873 9.4 RHAG SLC4A1
14 glycolytic process GO:0006096 9.35 ALDOA GPI HK1 PGK1 PKLR
15 glucose 6-phosphate metabolic process GO:0051156 9.33 G6PD GPI HK1
16 canonical glycolysis GO:0061621 9.02 ALDOA GPI HK1 PGK1 PKLR

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.87 AK1 EPB42 GCLC GSS HK1 PGK1
2 catalytic activity GO:0003824 9.67 ALDOA GCLC HK1 PKLR
3 magnesium ion binding GO:0000287 9.46 GCLC GSS NT5C3A PKLR
4 glucose binding GO:0005536 9.26 G6PD HK1
5 structural constituent of cytoskeleton GO:0005200 9.26 ANK1 EPB42 SPTA1 SPTB
6 ankyrin binding GO:0030506 8.8 RHAG SLC4A1 SPTB

Sources for Hemolytic Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....